ProPhase Labs, Inc. Disposal Group, Including Discontinued Operation, Assets
ProPhase Labs, Inc. (PRPH) had Disposal Group, Including Discontinued Operation, Assets of $57.41 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Assets
us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation · last filed 2026-08-19
- 2026-06-30: Disposal Group, Including Discontinued Operation, Assets $57.41M.
- 2026-03-31: Disposal Group, Including Discontinued Operation, Assets $58.47M; Disposal Group, Including Discontinued Operation, Assets as first filed $58.73M.
- 2025-12-31: Disposal Group, Including Discontinued Operation, Assets $59.87M; Disposal Group, Including Discontinued Operation, Assets as first filed $0.00.
- 2025-09-30: Disposal Group, Including Discontinued Operation, Assets $0.00.
| Period end | Disposal Group, Including Discontinued Operation, Assets | Disposal Group, Including Discontinued Operation, Assets as first filed |
|---|---|---|
| 2026-06-30 | $57.41M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $58.47M 10-Q/A · filed 2026-07-09 | $58.73M 10-Q · filed 2026-06-30 |
| 2025-12-31 | $59.87M 10-Q · filed 2026-08-19 | $0.00 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $11.58M 10-K · filed 2026-06-01 | |
| 2023-12-31 | $5.36M 10-K · filed 2025-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |